CHARMAINE HEBERT: Open Payments
NPI 1225341019 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$741 in 43 payments from 11 companies in 2025. Trend: 2023 $794 · 2024 $767 · 2025 $741
Food & beverage: $741
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 14 | $217 |
| ABBVIE INC. | 5 | $165 |
| Novo Nordisk Inc | 5 | $96 |
| Amgen Inc. | 4 | $62 |
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Exact Sciences Corporation | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 5 | $16 |
Products named: VRAYLAR, JARDIANCE, MOUNJARO, AIRSUPRA, Ozempic, OTEZLA, KISUNLA, TRINTELLIX.
Industry payments across LA — which companies pay providers there.
